What enzyme is deficient in Gaucher disease?

Gaucher disease is caused by deficiency of glucocerebrosidase, also called acid beta-glucosidase or lysosomal acid glucosylceramidase, because of variants in both copies of the GBA1 gene (autosomal recessive inheritance). The enzyme normally splits glucocerebroside into glucose and ceramide inside lysosomes. When it is deficient, glucocerebroside accumulates in macrophages, which become Gaucher cells that enlarge the spleen and liver, crowd the bone marrow and damage bone.

What are Gaucher cells?

Gaucher cells are macrophages swollen with stored glucocerebroside. Under the microscope their cytoplasm looks wrinkled, classically described as crumpled tissue paper, which separates them from the bubbly foam cells of Niemann-Pick disease. They collect in the spleen, liver, lymph nodes, bone marrow and sometimes the brain. Finding them in a bone marrow sample is a strong clue, but the diagnosis is confirmed with an enzyme assay in white blood cells and GBA1 genetic testing.

What are the three types of Gaucher disease?

Type 1, non-neuronopathic, makes up about 90% of cases and causes hepatosplenomegaly, anemia, thrombocytopenia and bone disease without primary brain involvement; it is especially common in Ashkenazi Jewish people. Type 2, acute neuronopathic, starts in infancy with rigidity, seizures and swallowing problems, and death usually occurs by age 2. Type 3, chronic neuronopathic, progresses more slowly and characteristically impairs horizontal eye movements, often alongside visceral and bone disease.

What bone problems does Gaucher disease cause?

Gaucher cells in the bone marrow cause bone pain, bone crises from bone infarcts (mostly in the pelvis and legs), osteopenia or osteoporosis and pathologic fractures. Avascular necrosis, usually of the femoral or humeral head, affects about 15% of patients and can lead to osteoarthritis that needs joint replacement. On plain films, the lower femur often flares into an Erlenmeyer flask shape, with thinning of the cortex.

How is Gaucher disease treated?

Enzyme replacement therapy with intravenous imiglucerase, velaglucerase alfa or taliglucerase alfa replaces the missing enzyme and treats the non-neurologic features. Substrate reduction therapy uses oral drugs that block glucosylceramide synthase: eliglustat for adults with type 1 whose CYP2D6 genotype shows they are extensive, intermediate or poor metabolizers, and miglustat for adults with mild to moderate type 1 who cannot receive enzyme replacement. Neither approach has been shown to treat the brain disease of types 2 and 3.

Is Gaucher disease linked to Parkinson disease?

Yes. People with Gaucher disease, and also carriers who have a single GBA1 variant, have an increased risk of developing Parkinson disease or parkinsonism. GBA1 variants can also increase the risk of dementia with Lewy bodies, although some people with a variant never develop either condition. The mechanism is still unclear; one idea is that reduced enzyme activity impairs the breakdown of toxic substances in nerve cells.

Gaucher Disease Sketch: Types, Bone Crises & Treatment

Gaucher disease is an autosomal recessive lysosomal storage disease caused by deficient glucocerebrosidase (acid β-glucosidase), encoded by GBA1. Glucocerebroside (glucosylceramide) builds up inside macrophages, which become Gaucher cells with wrinkled, "crumpled tissue paper" cytoplasm and pack the spleen, liver and bone marrow. The result is hepatosplenomegaly, anemia and thrombocytopenia, and bone disease (bone crises, Erlenmeyer flask femurs, avascular necrosis, fractures). Type 1 (about 90% of patients, no primary brain disease) is especially common in Ashkenazi Jewish people; types 2 and 3 are neuronopathic. GBA1 variants also raise the risk of Parkinson disease, even in carriers. Treatment is enzyme replacement (imiglucerase, velaglucerase alfa, taliglucerase alfa) or oral substrate reduction (eliglustat, miglustat); neither has been shown to treat the brain disease.

The 60-second sketch

Draw these eight pieces in order; each one is a testable fact.

A big circle (macrophage) with a small circle (lysosome) inside. In the lysosome write Glc–Cer: glucocerebroside is glucose attached to ceramide. Draw scissors labeled glucocerebrosidase (GBA1) and cross them out, because the enzyme that should cut it into glucose and ceramide is missing. Write AR in the corner.
Fill the macrophage with wavy, wrinkled lines. Stored lipid gives Gaucher cells their crumpled-tissue-paper cytoplasm, unlike the bubbly foam cells of Niemann-Pick disease.
Arrows from the cell to a huge spleen, a big liver and a marrow cavity. Gaucher cells infiltrate the mononuclear phagocyte system: hepatosplenomegaly. The spleen is enlarged in more than 90% of type 1 patients (sometimes massively, sometimes as the only sign) and the liver in 60-80%.
A few red cells and platelets dripping out of the marrow. Marrow infiltration plus hypersplenism cause anemia and thrombocytopenia: fatigue, easy bruising, nosebleeds.
A femur shaped like a laboratory flask. That is the Erlenmeyer flask deformity: the lower femur flares during childhood. Add lightning bolts in the pelvis and legs (bone crises from bone infarcts), a blacked-out femoral head (avascular necrosis, in about 15%, also at the humeral head) and cracks (osteopenia and pathologic fractures).
A brain labeled 1, 2, 3. Type 1 spares the brain. Type 2 is an infant with rigidity and seizures, with death usually by age 2. Type 3 progresses more slowly, with trouble moving the eyes horizontally.
"PD" and "M-protein" in the margin. GBA1 variants raise the risk of Parkinson disease and dementia with Lewy bodies, and patients have more gammopathies and multiple myeloma.
An IV bag and a pill. The IV bag (enzyme replacement) refills the scissors but doesn't treat the brain; the pill (substrate reduction) turns down the tap by blocking glucosylceramide synthase.

Say it out loud: "A wrinkled macrophage stuffed with glucocerebroside swells the spleen, steals the blood counts and breaks the bones; refill the enzyme or shut the tap."

The core facts

Feature	Gaucher disease
Deficient enzyme	Glucocerebrosidase (acid β-glucosidase, also called lysosomal acid glucosylceramidase)
Gene and inheritance	GBA1 on chromosome 1; autosomal recessive
Normal reaction	Glucocerebroside → glucose + ceramide
Stored lipid	Glucocerebroside (glucosylceramide)
Storage cell	Macrophages (Gaucher cells) in the spleen, liver, lymph nodes, bone marrow or brain
Frequency	1 in 50,000-100,000 overall; type 1 affects 1 in 500-1,000 Ashkenazi Jewish people (MedlinePlus), and about 1 in 12 is a carrier (Merck)

Ashkenazi founder variants. In a 2017 review, four variants (N370S, 84GG, L444P and IVS2+1) accounted for about 90% of mutant alleles in Ashkenazi Jewish patients with type 1, and N370S alone for 75-80%. One N370S allele is considered to rule out neuronopathic disease, while L444P homozygotes are at high risk of type 2 or 3.

Old vs new variant names. The familiar names use legacy numbering that skips the 39-amino-acid signal peptide; current HGVS names count it, so N370S = c.1226A>G, p.Asn409Ser (N409S) and L444P = c.1448T>C, p.Leu483Pro (L483P). Newer papers and genetic reports use the new names.

Types 1, 2 and 3

	Type 1 (non-neuronopathic)	Type 2 (acute neuronopathic)	Type 3 (chronic neuronopathic)
Share and enzyme	About 90%; most residual activity	Rarest; least residual activity	In between
Onset	Childhood to adulthood	Infancy; a perinatal-lethal form can cause hydrops fetalis	Childhood; eye-movement signs usually before age 20
Brain	No primary CNS disease	Rapid decline: rigidity, seizures, dysphagia	Slowed or absent horizontal eye movements; some develop dementia and ataxia
Body	Hepatosplenomegaly, cytopenias, bone disease, growth failure, delayed puberty	Hepatosplenomegaly	Visceral and bone disease like type 1; type 3c calcifies heart valves
Outlook	Longest survival	Death usually by age 2	Many who reach adolescence live for years

Diagnosis

Confirm with enzyme testing: low acid β-glucosidase activity in white blood cells (total leukocytes or mononuclear cells), plus GBA1 genetic testing.
Bone marrow biopsy isn't required when enzyme and genetic results are conclusive. Gaucher cells in a marrow done for cytopenias are a clue, not the confirmatory test.
Biomarkers to follow the disease: chitotriosidase (made in large amounts by Gaucher cells), CCL18 (10-50 times control levels) and glucosylsphingosine (lyso-Gb1), which beats both on sensitivity and specificity. Ferritin is raised in more than 85%.
Plain films: Erlenmeyer flask flaring and cortical thinning of the long bones.

Treatment

Approach	Drugs	How it works	Key facts
Enzyme replacement therapy (ERT)	Imiglucerase, velaglucerase alfa, taliglucerase alfa (IV)	Recombinant glucocerebrosidase whose mannose-terminated glycans target macrophages	Imiglucerase is labeled for the non-CNS manifestations of type 1 or 3 in adults and children, with a boxed warning for hypersensitivity reactions, including anaphylaxis
Substrate reduction therapy (SRT)	Eliglustat (oral)	Inhibits glucosylceramide synthase, so less glucocerebroside is made	Adults with type 1 who are CYP2D6 extensive, intermediate or poor metabolizers; not for ultrarapid metabolizers or an undetermined genotype. CYP2D6 and CYP3A inhibitors raise levels and the risk of PR, QTc or QRS prolongation; avoid in pre-existing heart disease or long QT
SRT	Miglustat (oral)	Same target	Adults with mild to moderate type 1 for whom ERT is not an option (allergy, hypersensitivity, poor venous access); it crosses the blood-brain barrier but hasn't improved neurologic type 3 disease

Merck also lists splenectomy and stem cell transplantation, and there is no specific treatment for type 2.

Gaucher vs the other sphingolipidoses

Disease	Deficient enzyme	Stored lipid	Inheritance	Signature clues
Gaucher	Glucocerebrosidase	Glucocerebroside	AR	Crumpled-tissue-paper macrophages, hepatosplenomegaly, cytopenias, bone crises, Erlenmeyer flask
Niemann-Pick A/B	Acid sphingomyelinase	Sphingomyelin	AR	Foam cells, hepatosplenomegaly; type A adds a cherry-red spot, frequent respiratory infections and death by about age 3
Tay-Sachs	Hexosaminidase A	GM2 ganglioside	AR	Cherry-red spot, exaggerated startle, early blindness, no hepatosplenomegaly; Ashkenazi association
Fabry	α-Galactosidase A	Globotriaosylceramide	X-linked	Hand and foot pain, angiokeratomas, reduced sweating, corneal clouding, kidney failure, cardiomyopathy, stroke; heterozygous females often affected
Krabbe	Galactocerebrosidase	Galactocerebroside, psychosine	AR	Infant irritability, stiffness, unexplained fevers; globoid cells; myelin loss
Metachromatic leukodystrophy	Arylsulfatase A	Sulfatides	AR	Central and peripheral demyelination: speech loss and gait problems from the second year of life, psychiatric onset in adults

Every enzyme in the pathway is mapped in the sphingolipid metabolism table. Separate the look-alikes with the Niemann-Pick mnemonic, the Tay-Sachs 5-second rule, the Fabry quick tips and the Krabbe disease guide.

How USMLE tests Gaucher disease

Buzzwords: "crumpled tissue paper" macrophages = Gaucher; "foam cells" = Niemann-Pick; "globoid cells" = Krabbe.
Young adult with splenomegaly, low platelets and bone pain, often of Ashkenazi Jewish descent = type 1 Gaucher; confirm with a leukocyte enzyme assay and GBA1 testing.
Cherry-red spot: with a big liver and spleen, think Niemann-Pick A; with a normal abdomen, think Tay-Sachs.
Parkinson disease link: GBA1 carriers and patients both have a higher risk; review the Parkinson disease flowchart.
Pharm hooks: eliglustat needs CYP2D6 genotyping first, and ERT does not treat the brain.
Inheritance: every disease in the table is autosomal recessive except Fabry (X-linked).

Practice question

A 27-year-old woman of Ashkenazi Jewish descent has fatigue, easy bruising, frequent nosebleeds and two episodes of severe thigh pain that each lasted several days. Her spleen is palpable 8 cm below the left costal margin and her liver edge 3 cm below the right. Eye movements and the rest of the neurologic exam are normal. Hemoglobin is 9.8 g/dL and platelets are 62,000/mm³. Radiographs show flaring of both distal femurs. A bone marrow aspirate shows large macrophages whose cytoplasm looks like crumpled tissue paper. Accumulation of which substance best explains her findings?

A. Galactocerebroside
B. Globotriaosylceramide
C. Glucocerebroside
D. GM2 ganglioside
E. Sphingomyelin
F. Sulfatides

Answer: C. Splenomegaly, anemia and thrombocytopenia, bone crises, Erlenmeyer flask femurs and crumpled-tissue-paper macrophages in an adult with a normal neurologic exam add up to type 1 Gaucher disease: glucocerebroside fills macrophages because glucocerebrosidase is deficient. Confirm with a leukocyte acid β-glucosidase assay and GBA1 testing, then treat with ERT, or with eliglustat after CYP2D6 genotyping.

A (Krabbe disease): galactocerebroside and psychosine destroy myelin in infants, causing irritability, stiffness, unexplained fevers and globoid cells.
B (Fabry disease): X-linked; burning hand and foot pain, angiokeratomas, reduced sweating, kidney failure and stroke, without Gaucher cells.
D (Tay-Sachs disease): an infant with a cherry-red spot, exaggerated startle and regression, and a normal-sized liver and spleen.
E (Niemann-Pick disease, types A/B): sphingomyelin fills foamy macrophages, not wrinkled ones; type A adds a cherry-red spot and early death.
F (metachromatic leukodystrophy): sulfatides demyelinate central and peripheral nerves, causing gait problems and regression in children or psychiatric symptoms in adults.

Key takeaways

Gaucher disease = autosomal recessive glucocerebrosidase (GBA1) deficiency → glucocerebroside in macrophages.
Crumpled-tissue-paper Gaucher cells cause hepatosplenomegaly, anemia, thrombocytopenia, bone crises, Erlenmeyer flask femurs and avascular necrosis.
Type 1 (about 90%) spares the brain and is common in Ashkenazi Jewish people (N370S); type 2 is fatal in infancy; type 3 brings horizontal eye-movement problems.
Diagnose with a leukocyte enzyme assay plus GBA1 testing; marrow biopsy isn't required.
Treat with ERT (imiglucerase, velaglucerase alfa, taliglucerase alfa) or SRT (eliglustat after CYP2D6 genotyping; miglustat for adults with mild to moderate type 1 when ERT isn't an option).
GBA1 variants raise Parkinson disease risk, even in carriers.